AU2002219021A1 - Variant growth hormone molecules conjugated with macromolecular compounds - Google Patents
Variant growth hormone molecules conjugated with macromolecular compoundsInfo
- Publication number
- AU2002219021A1 AU2002219021A1 AU2002219021A AU2002219021A AU2002219021A1 AU 2002219021 A1 AU2002219021 A1 AU 2002219021A1 AU 2002219021 A AU2002219021 A AU 2002219021A AU 2002219021 A AU2002219021 A AU 2002219021A AU 2002219021 A1 AU2002219021 A1 AU 2002219021A1
- Authority
- AU
- Australia
- Prior art keywords
- growth hormone
- macromolecular compounds
- molecules conjugated
- hormone molecules
- variant growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000018997 Growth Hormone Human genes 0.000 title 1
- 108010051696 Growth Hormone Proteins 0.000 title 1
- 239000000122 growth hormone Substances 0.000 title 1
- 229920002521 macromolecule Polymers 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26141101P | 2001-01-11 | 2001-01-11 | |
DKPA200100042 | 2001-01-11 | ||
US60/261,411 | 2001-01-11 | ||
DKPA200100042 | 2001-01-11 | ||
PCT/DK2002/000017 WO2002055532A2 (en) | 2001-01-11 | 2002-01-10 | Variant growth hormone molecules conjugated with macromolecular compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002219021A1 true AU2002219021A1 (en) | 2002-07-24 |
Family
ID=26068940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002219021A Abandoned AU2002219021A1 (en) | 2001-01-11 | 2002-01-10 | Variant growth hormone molecules conjugated with macromolecular compounds |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1352062A2 (en) |
JP (1) | JP2004524020A (en) |
AU (1) | AU2002219021A1 (en) |
WO (1) | WO2002055532A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
BR0214451A (en) * | 2001-11-20 | 2006-05-30 | Pharmacia Corp | chemically modified human growth hormone conjugates |
AU2003254641A1 (en) * | 2002-08-28 | 2004-03-19 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
JP2008502301A (en) * | 2003-10-10 | 2008-01-31 | ノボ ノルディスク アクティーゼルスカブ | Peptide conjugation |
CA2552043A1 (en) * | 2004-01-21 | 2005-08-04 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
NZ555386A (en) * | 2004-12-22 | 2011-01-28 | Ambrx Inc | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
JP2008543297A (en) * | 2005-06-15 | 2008-12-04 | ノボ ノルディスク ヘルス ケア アーゲー | Conjugation of growth hormone via transglutaminase |
JP2009506096A (en) | 2005-08-30 | 2009-02-12 | ノボ ノルディスク ヘルス ケア アーゲー | Liquid preparation of pegylated growth hormone |
EP2040757A2 (en) | 2006-07-07 | 2009-04-01 | Novo Nordisk Health Care AG | New protein conjugates and methods for their preparation |
LT3050576T (en) * | 2008-04-29 | 2021-07-12 | Ascendis Pharma Endocrinology Division A/S | Pegylated recombinant human growth hormone compounds |
WO2010015668A1 (en) | 2008-08-06 | 2010-02-11 | Novo Nordisk A/S | Conjugated proteins with prolonged in vivo efficacy |
AU2010207725B2 (en) | 2009-01-22 | 2015-06-11 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
US8841249B2 (en) | 2009-08-06 | 2014-09-23 | Novo Nordisk A/S | Growth hormones with prolonged in-vivo efficacy |
CA2787895A1 (en) * | 2010-01-22 | 2011-07-28 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
AU2011208625C1 (en) | 2010-01-22 | 2022-08-18 | Novo Nordisk Health Care Ag | Growth hormones with prolonged in-vivo efficacy |
WO2012010516A1 (en) | 2010-07-22 | 2012-01-26 | Novo Nordisk Health Care Ag | Growth hormone conjugates |
WO2014139994A1 (en) | 2013-03-11 | 2014-09-18 | Novo Nordisk Health Care Ag | Growth hormone compounds |
US11045523B2 (en) | 2013-04-05 | 2021-06-29 | Novo Nordisk Healthcare Ag | Formulation of growth hormone albumin-binder conjugate |
EP3303380B1 (en) | 2015-06-02 | 2020-01-15 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
MA43348A (en) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | PROTEIN CONJUGATES |
CN114835797A (en) * | 2015-11-16 | 2022-08-02 | Ubi蛋白公司 | Method for extending protein half-life |
EP3606560A2 (en) | 2017-04-05 | 2020-02-12 | Novo Nordisk A/S | Oligomer extended insulin-fc conjugates |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0458064B1 (en) * | 1990-05-04 | 1998-02-25 | American Cyanamid Company | Stabilization of somatotropins by modification of cysteine residues |
WO1995011987A1 (en) * | 1993-10-29 | 1995-05-04 | Incyte Pharmaceuticals, Inc. | Chimeric proteins including protease nexin-1 variants |
DK1568772T3 (en) * | 1995-09-21 | 2010-10-18 | Genentech Inc | Variants of Human Growth Hormone |
ES2297889T3 (en) * | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | DERIVATIVES OF HORMONE OF GROWTH AND RELATED PROTEINS. |
CA2359345A1 (en) * | 1999-01-14 | 2000-07-20 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
-
2002
- 2002-01-10 AU AU2002219021A patent/AU2002219021A1/en not_active Abandoned
- 2002-01-10 EP EP02729417A patent/EP1352062A2/en not_active Withdrawn
- 2002-01-10 JP JP2002556600A patent/JP2004524020A/en active Pending
- 2002-01-10 WO PCT/DK2002/000017 patent/WO2002055532A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2004524020A (en) | 2004-08-12 |
WO2002055532A3 (en) | 2002-09-19 |
EP1352062A2 (en) | 2003-10-15 |
WO2002055532A2 (en) | 2002-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002219021A1 (en) | Variant growth hormone molecules conjugated with macromolecular compounds | |
AU2002342653A1 (en) | Modified growth hormone | |
AU2002234854A1 (en) | An improved patch panel | |
AU7578600A (en) | Multi-dose syringe driver | |
AU2002352688A1 (en) | Telecommunications patch panel | |
AU5628600A (en) | Insulin-like growth factor agonist molecules | |
AU7538300A (en) | Dual-band microstrip antenna | |
AU7760500A (en) | Pavement patch material | |
AU5062900A (en) | Radio terminal for browsing the internet | |
AU2003299189A1 (en) | Patch | |
AUPQ339899A0 (en) | Novel molecules | |
AU2001277618A1 (en) | Saw device with integral patch antenna | |
AU2002331681A1 (en) | Treatment patch | |
AU7030200A (en) | Edgings | |
AU3479000A (en) | Dermatological patch | |
AU2001292786A1 (en) | Sulfur-containing cathode | |
AU2001236306A1 (en) | Tuneable antenna | |
AU2001245888A1 (en) | Growth factor binding molecules | |
AU2002311389A1 (en) | Crosslinkable composition | |
AU7829100A (en) | Low profile tunable antenna | |
EP2520289B8 (en) | Norethisterone-containing patch | |
AU2002213723A1 (en) | Capacitively switched matrixed el display | |
AU7306300A (en) | Bottle with pump | |
AU6319600A (en) | Patch | |
AU7060300A (en) | Internet jack |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |